SERRATHOR TRIAL : Interest of the Novel Serratus Plane Block in Post Operative Analgesia After Video-Assisted Thoracoscopic Lobectomy

SERRATHOR Trial : Analgesic Effect of Serratus Plane Block After Video-Assisted Thoracoscopic Surgery Lobectomy

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03867695

Acronym

SERRATHOR

Enrollment

Registered

2019-03-08

Start date

2019-09-03

Completion date

2020-10-30

Last updated

2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lobectomy, Pain Post Operative, Regional Anesthesia, Video Assisted Thoracoscopic Surgery

Keywords

Serratus plane block, Analgesia after VATS, Lobectomy VATS

Brief summary

Pain after thoracic surgery remains a challenge for anesthetists. Although VATS for lobectomy is associated with fewer complications compared to thoracotomy, pain after VATS needs to be treated with opioids. Opioids may lead to PONV, respiratory depression, sedation and pruritus. As part of multimodal analgesia and opioids sparing, several local regional techniques has been described: paravertebral block, thoracic epidural analgesia, intercostal block. To date, there is no gold standard for regional anesthesia after VATS. Serratus plane block is a local regional technique, recently described for analgesia after breast surgery and ribs fracture. In our hospital center, since 2016, we used the Serratus plane block for patients scheduled for lobectomy VATS : a local retrospective trial showed that SPB was associated with a lower consumption of morphine. The purpose of this randomized controlled double blinded study is to evaluate the analgesic effect of the Serratus plane block, added to a general anesthesia on post operative pain control after VATS lobectomy.

Interventions

DRUGRopivacaine

At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.

DRUGsterile saline

Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* All patients undergoing lobectomy VATS * Older \> 18 years * Patients who meet criteria of ASA 1 to 3 class

Exclusion criteria

* Patient's refusal to participate in the study * Psychiatric disorder (impossibility to collect the informed consent) * Patient under juridical protection * On going an other study * Non balanced epilepsy * 3 grade auriculo-ventricular heart block without pacing * Severe hepatocellular insufficiency * Anti arrhythmic treatment : class III of the Vaughan William's classification * Pregnant patient or/and breastfeeding * History of opioid abuse * Allergy to local anesthetic drug or opioids

Design outcomes

Primary

Measure	Time frame	Description
Total intravenous morphine consumption (mg) in the PACU and department.	24 hours	Including the dose of titration while the patient is in PACU and PCA up to 24h postoperatively.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORBob HEGER

Les Hôpitaux Universitaires de Strasbourg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026